Your browser doesn't support javascript.
loading
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
Planchard, David; Yokoi, Takashi; McCleod, Michael J; Fischer, Jürgen R; Kim, Young-Chul; Ballas, Marc; Shi, Kelvin; Soria, Jean-Charles.
Afiliação
  • Planchard D; Department of Medical Oncology, Gustave Roussy, Villejuif, France. Electronic address: David.PLANCHARD@gustaveroussy.fr.
  • Yokoi T; First Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
  • McCleod MJ; Florida Cancer Specialists and Research Institute, Fort Myers, FL.
  • Fischer JR; Department of Internal Medicine II, Lungenklinik Löwenstein GmbH, Löwenstein, Germany.
  • Kim YC; Department of Internal Medicine, Chonnam National University Medical School, Hwasun Hospital, Hwasun, Jeonnam, South Korea.
  • Ballas M; Global Medical Development (GMD), AstraZeneca, Gaithersburg, MD.
  • Shi K; Biometrics and Information Sciences, AstraZeneca, Gaithersburg, MD.
  • Soria JC; DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy, Villejuif, France.
Clin Lung Cancer ; 17(3): 232-236.e1, 2016 05.
Article em En | MEDLINE | ID: mdl-27265743

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article